Localizing parkinsonism based on focal brain lesions

Area of Science:

• Neuroscience
• Neurology
• Brain Imaging

Background:

• Parkinsonism (bradykinesia, rigidity, tremor) is often linked to Parkinson's disease and substantia nigra cell loss.
• However, parkinsonism presents in various disorders and doesn't always correlate with nigrostriatal pathology, questioning the primary brain regions involved.
• The precise neuroanatomical basis of parkinsonism remains incompletely understood.

Purpose of the Study:

• To identify the brain regions and networks causally linked to new-onset parkinsonism using focal brain lesions.
• To investigate if diverse lesion locations causing parkinsonism converge onto a common functional network.
• To explore the potential of this identified network as a target for therapeutic interventions.

Main Methods:

• Analysis of 29 cases with new-onset parkinsonism following focal brain lesions.
• Application of lesion network mapping utilizing the human brain connectome.
• Correlation of lesion connectivity patterns with neurodegenerative disease atrophy and treatment responses.

Main Results:

• Only 31% of lesions causing parkinsonism affected the substantia nigra; lesions were widespread across cortical and subcortical areas.
• Lesion locations were functionally connected to a common network including the midbrain, basal ganglia, cingulate cortex, and cerebellum.
• Connectivity to the claustrum was the most sensitive and specific predictor of parkinsonism; this pattern mirrored atrophy in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy.
• Lesion connectivity predicted medication response and aligned with effective deep brain stimulation targets.

Conclusions:

• Parkinsonism arises from damage to a distributed brain network rather than solely the substantia nigra.
• The claustrum plays a critical role within this network.
• These findings provide insights into the neuroanatomy of parkinsonism and suggest potential alternative therapeutic targets beyond dopaminergic medication.